The National Institute for Health and Care Excellence

First treatment for vitiligo recommended by NICE for NHS use, bringing hope to over 80,000 people

More than 80,000 adults and teenagers across England suffering with a chronic skin condition could have their lives transformed after NICE today (Tuesday, 24 February) recommended the first licensed ...
National Institute for Health and Care Excellence

Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional costs to the NHS

This means the medicines should not be provided on the NHS as they are not good value for money. Last month the appraisal committee met to consider new information submitted as part of its additional ...
National Institute for Health and Care Excellence

Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)

NICE is unable to make a recommendation on canagliflozin (Invokana) for treating type 2 diabetes in children and young people 10 to 17 years. This is because the company did not provide an evidence ...
The National Institute for Health and Care Excellence

NICE publishes first quality standard to improve care for people with rare diseases

For too long, people living with rare diseases have faced uncertainty, delays, and unacceptable variation in the care they receive. The launch of this quality standard is a watershed moment. For the ...
The National Institute for Health and Care Excellence

More than 20,000 people benefitting from innovative migraine pills recommended by NICE

NICE recommended rimegepant in 2023 for treating migraine and preventing episodic attacks (between 4 and 14 migraines per month), and atogepant in 2024 for preventing both episodic and chronic ...
The National Institute for Health and Care Excellence

Driving biosimilar adoption through collaboration

Looking ahead, the biosimilar taskforce will become a strategic cornerstone of the NICE Whole Lifecycle Approach programme, the 10-Year Health Plan and the drive for rapid uptake of biosimilars. This ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) TA1137 25 February 2026 25 February 2026 ...
National Institute for Health and Care Excellence

Suspected sepsis: recognition, diagnosis and early management

This guideline has been updated and replaced by NICE's guidelines on suspected sepsis in people aged 16 or over (NG253), suspected sepsis in under 16s (NG254) and suspected sepsis in pregnant or ...
National Institute for Health and Care Excellence

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal guidance TA673 Published: 17 ...
National Institute for Health and Care Excellence

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies

Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies. Next review: More ...
National Institute for Health and Care Excellence

Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...